BSX Stock Recent News
BSX LATEST HEADLINES
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
Shares of Boston Scientific (BSX) hit an all-time high Wednesday as the maker of medical equipment reported better-than-anticipated quarterly results and boosted its guidance on demand for its cardiovascular devices, including a newly approved product to treat irregular heartbeats.
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Boston Scientific (BSX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.47 per share a year ago.
The medical-device company tops first-quarter sales and profit estimates.
Medical device maker Boston Scientific raised its annual profit forecast on Wednesday as the company banks on resilient demand for its heart devices, with post-pandemic elective surgical procedures picking up pace.
Boston Scientific Corp.'s stock BSX, +1.43% rose 2.7% early Wednesday, after the medical tech company's first-quarter earnings beat analyst estimates. The company had net income of $495 million, or 33 cents a share, for the quarter, up from $300 million, or 21 cents a share, in the year-earlier period.
Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.